度普利尤单抗在一名患有特应性皮炎、重度哮喘和HIV感染患者中的应用。
Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection.
作者信息
Brodska Petra, Panzner Petr, Sedlacek Dalibor, Terl Milan, Cetkovska Petra
机构信息
Department of Dermatology and Venereology, Charles University, Pilsen, Czech Republic.
Institute of Immunology and Allergology, Charles University, Pilsen, Czech Republic.
出版信息
Dermatol Ther. 2020 Nov;33(6):e14159. doi: 10.1111/dth.14159. Epub 2020 Sep 9.
Dupilumab is a monoclonal antibody against interleukin 4 (IL-4) receptor α that blocks signaling from IL-4 and IL-13, essential mediators of T helper 2 (Th2) pathway. To date, all clinical trials investigating the use of dupilumab excluded patients with human immunodeficiency virus. Herein, we describe the safe and successful use of dupilumab in a patient with atopic dermatitis, severe therapy resistant asthma, and HIV infection.
度普利尤单抗是一种抗白细胞介素4（IL-4）受体α的单克隆抗体，可阻断IL-4和IL-13的信号传导，IL-4和IL-13是辅助性T细胞2（Th2）途径的重要介质。迄今为止，所有研究度普利尤单抗使用的临床试验都排除了人类免疫缺陷病毒患者。在此，我们描述了度普利尤单抗在一名患有特应性皮炎、严重难治性哮喘和HIV感染患者中的安全且成功的应用。
Zotero 插件